These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 31144585)

  • 1. Response to Hyun J.W. et al. "Longitudinal analysis of serum neurofilament light chain: A potential therapeutic monitoring biomarker for multiple sclerosis".
    Akgün K; Ziemssen T
    Mult Scler; 2020 May; 26(6):742-743. PubMed ID: 31144585
    [No Abstract]   [Full Text] [Related]  

  • 2. Neurofilament light chain: An important step toward a disease biomarker in multiple sclerosis.
    Berger T; Stüve O
    Neurology; 2019 Mar; 92(10):451-452. PubMed ID: 30737335
    [No Abstract]   [Full Text] [Related]  

  • 3. Challenges and Opportunities for the Promising Biomarker Blood Neurofilament Light Chain.
    Abdelhak A; Kuhle J; Green AJ
    JAMA Neurol; 2023 Jun; 80(6):542-543. PubMed ID: 37010852
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CSF neurofilament light: A universal risk biomarker in multiple sclerosis?
    Khalil M; Salzer J
    Neurology; 2016 Sep; 87(11):1068-9. PubMed ID: 27521432
    [No Abstract]   [Full Text] [Related]  

  • 5. Neurofilament in CSF-A biomarker of disease activity and long-term prognosis in multiple sclerosis.
    Soelberg Sorensen P; Sellebjerg F
    Mult Scler; 2016 Aug; 22(9):1112-3. PubMed ID: 27364323
    [No Abstract]   [Full Text] [Related]  

  • 6. Serum neurofilament light chain is a biomarker of acute and chronic neuronal damage in early multiple sclerosis.
    Siller N; Kuhle J; Muthuraman M; Barro C; Uphaus T; Groppa S; Kappos L; Zipp F; Bittner S
    Mult Scler; 2019 Apr; 25(5):678-686. PubMed ID: 29542376
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ella versus Simoa Serum Neurofilament Assessment to Monitor Treatment Response in Highly Active Multiple Sclerosis Patients.
    Nötzel M; Werder LI; Ziemssen T; Akgün K
    Int J Mol Sci; 2022 Oct; 23(20):. PubMed ID: 36293227
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relationship Between Serum Neurofilament Light and Multiple Sclerosis Disability Progression: Clear as Mud.
    Goldschmidt C; Fox RJ
    Neurology; 2021 Nov; 97(19):887-888. PubMed ID: 34504029
    [No Abstract]   [Full Text] [Related]  

  • 9. Disease biomarkers in multiple sclerosis: current serum neurofilament light chain perspectives.
    Jakimovski D; Dwyer MG; Bergsland N; Weinstock-Guttman B; Zivadinov R
    Neurodegener Dis Manag; 2021 Aug; 11(4):329-340. PubMed ID: 34196596
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neurofilament light chain as a marker for cortical atrophy in multiple sclerosis without radiological signs of disease activity.
    Ineichen BV; Moridi T; Ewing E; Ouellette R; Manouchehrinia A; Stawiarz L; Ferreira D; Muehlboeck SJ; Kuhle J; Westman E; Leppert D; Hillert J; Olsson T; Kockum I; Piehl F; Granberg T
    J Intern Med; 2021 Aug; 290(2):473-476. PubMed ID: 33871105
    [No Abstract]   [Full Text] [Related]  

  • 11. Author Response: Blood Neurofilament Light in Progressive Multiple Sclerosis: Post Hoc Analysis of 2 Randomized Controlled Trials.
    Leppert D; Kropshofer H; Häring D; Dahlke F; Patil A; Meinert R; Tomic D; Kappos L; Kuhle J
    Neurology; 2022 Oct; 99(14):631. PubMed ID: 36192181
    [No Abstract]   [Full Text] [Related]  

  • 12. Reader Response: Blood Neurofilament Light in Progressive Multiple Sclerosis: Post Hoc Analysis of 2 Randomized Controlled Trials.
    Barro C
    Neurology; 2022 Oct; 99(14):630-631. PubMed ID: 36192183
    [No Abstract]   [Full Text] [Related]  

  • 13. Serum neurofilament light and prediction of multiple sclerosis in clinically isolated syndrome.
    Zetterberg H; Svenningsson A
    Neurology; 2019 Feb; 92(7):313-314. PubMed ID: 30635493
    [No Abstract]   [Full Text] [Related]  

  • 14. Neurofilament in clinical practice: Is the multiple sclerosis community ready?
    Moccia M; Terracciano D; Brescia Morra V; Castaldo G
    Mult Scler; 2024 May; 30(6):643-645. PubMed ID: 38605490
    [No Abstract]   [Full Text] [Related]  

  • 15. Combined Neurofilament Light and Optical Coherence Tomography Better Predicts Multiple Sclerosis Disease Activity Than Either Measure Alone.
    Krämer J; Wiendl H; Meuth SG; Albrecht P
    Neurol Neuroimmunol Neuroinflamm; 2021 Sep; 8(5):. PubMed ID: 34348970
    [No Abstract]   [Full Text] [Related]  

  • 16. Serum neurofilament as a predictor of disease worsening and brain and spinal cord atrophy in multiple sclerosis.
    Barro C; Benkert P; Disanto G; Tsagkas C; Amann M; Naegelin Y; Leppert D; Gobbi C; Granziera C; Yaldizli Ö; Michalak Z; Wuerfel J; Kappos L; Parmar K; Kuhle J
    Brain; 2018 Aug; 141(8):2382-2391. PubMed ID: 29860296
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Decreased neurofilament light chain levels in estriol-treated multiple sclerosis.
    Voskuhl R; Kuhle J; Siddarth P; Itoh N; Patel K; MacKenzie-Graham A
    Ann Clin Transl Neurol; 2022 Aug; 9(8):1316-1320. PubMed ID: 35770318
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is CSF neurofilament light chain measurement relevant for MS?
    Matsui M
    Neurol Neuroimmunol Neuroinflamm; 2020 Nov; 7(6):. PubMed ID: 32928895
    [No Abstract]   [Full Text] [Related]  

  • 19. Plasma neurofilament light in progressive multiple sclerosis.
    Zetterberg H
    Acta Neurol Scand; 2020 Jan; 141(1):14-15. PubMed ID: 31618445
    [No Abstract]   [Full Text] [Related]  

  • 20. Neurofilament light in blood - What more is needed for clinical implementation in multiple sclerosis?
    Zetterberg H
    EBioMedicine; 2020 Jul; 57():102826. PubMed ID: 32574951
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.